FMA
JNCE

FNY Managed Accounts’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

FNY Managed Accounts’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-440
Closed -$9K – 690
2017
Q1 		$9K Buy
+440
New +$9.32K 0.03% 526

Other funds holding JNCE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FNY Managed Accounts's JNCE Position: Q2 2017 in Review

FNY Managed Accounts sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2017, closing a stake of 440 shares — an estimated $9K sold.

FNY Managed Accounts first reported a position in JNCE in Q1 2017 and held it in 1 quarter. The position peaked at $9K in Q1 2017. 72 funds tracked by Wall St. Rank hold JNCE as of Q2 2017.

  • FNY Managed Accounts reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • FNY Managed Accounts sold 440 Jounce Therapeutics, Inc. Common Stock shares in Q2 2017, an estimated $9K.
  • FNY Managed Accounts first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 1 quarter.
  • FNY Managed Accounts's Jounce Therapeutics, Inc. Common Stock position peaked at $9K in Q1 2017.
  • 72 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2017.

Based on FNY Managed Accounts's 13F filing for Q2 2017, filed 10 Aug 2017.